Saniona

Saniona Chairman J. Donald deBethizy and CEO Rami Levin, as well as additional members of the board and management, purchase Saniona shares in the open market

See press release here.

Saniona publishes its year-end report for 2020

See press release here.

Saniona Receives Feedback from U.S. FDA Providing a Regulatory Path Forward for Tesomet in Hypothalamic Obesity

See press release here.

Saniona Receives U.S. FDA Orphan Drug Designation for Tesomet in Prader-Willi Syndrome

See press release here.

s

See allNews

Proprietary Pipeline Read more about our Proprietary Pipeline

We have a broad portfolio of potential drug candidates in preclinical or clinical stages.

Tesomet for treatment of Prader-Willi Syndrome and Hypothalamic Obesity

SAN711 for the treatment of rare neuropathic disorders

SAN903 for rare inflammatory and fibrotic disorders